Company Encyclopedia
View More
name
Novo Nordisk AS
NVO.US
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy.
4.729 T
NVO.USMarket value -Rank by Market Cap -/-

Financial Score

26/12/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking6/186
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE71.46%A
    • Profit Margin32.88%A
    • Gross Margin80.70%A
  • Growth ScoreB
    • Revenue YoY19.19%B
    • Net Profit YoY11.95%C
    • Total Assets YoY35.27%A
    • Net Assets YoY47.93%A
  • Cash ScoreB
    • Cash Flow Margin304.13%C
    • OCF YoY19.19%B
  • Operating ScoreB
    • Turnover0.69B
  • Debt ScoreD
    • Gearing Ratio66.84%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    FDA approved Novo Nordisk A/S' Wegovy pill (25mg oral semaglutide) for weight loss. 16.6% mean weight loss in trial.

    The FDA has approved Novo Nordisk's Wegovy pill (25mg oral semaglutide) for weight loss, marking the first oral GLP-1 receptor agonist approved for this purpose. Clinical trials showed a 16.6% mean weight loss, with some participants achieving over 20% reduction. The pill's efficacy is comparable to the injectable version. Novo Nordisk plans to launch it soon.

    Unusual Whales·
    US
    NVO
    -0.30%
    Unusual Whales·
    US
    NVO
    -0.30%

    Best Pharmaceutical Stocks To Follow Now - December 26th

    MarketBeat's stock screener tool highlights Eli Lilly, Novo Nordisk, and Pfizer as pharmaceutical stocks to watch. These stocks are influenced by clinical trials, regulatory approvals, and drug-pricing dynamics, making them volatile. Eli Lilly, Novo Nordisk, and Pfizer have high trading volumes recently. MarketBeat suggests Eli Lilly has a Moderate Buy rating, but top analysts recommend other stocks as better buys.

    Market Beat·
    US
    LLY
    +0.07%
    US
    NVO
    -0.30%
    Market Beat·
    US
    LLY
    +0.07%
    US
    NVO
    -0.30%

    Should You Invest in Ozempic Maker Novo Nordisk in 2026?

    Novo Nordisk's stock has declined due to competition and management changes, but the FDA's approval of its Wegovy pill, an oral GLP-1 drug for weight management, could boost its growth. The pill's market entry in January may help Novo Nordisk regain momentum, potentially making it a strong investment by 2026. Despite recent challenges, the company's revenue and earnings have grown, and its stock is considered undervalued, offering a 3.3% dividend yield. Analysts suggest considering Novo Nordisk as a market-beating investment opportunity.

    Yahoo Finance·
    US
    NVO
    -0.30%
    Yahoo Finance·
    US
    NVO
    -0.30%

    What Does the Market Think About Novo Nordisk AS?

    Novo Nordisk AS's short interest as a percent of float has decreased by 3.41%, with 28.49 million shares sold short, representing 0.85% of available shares. It would take traders 2.09 days to cover these positions. The company's short interest is lower than its peers, whose average is 3.66%. This decrease in short interest may indicate a more bullish market sentiment towards Novo Nordisk AS.

    benzinga_article·
    US
    NVO
    -0.30%
    benzinga_article·
    US
    NVO
    -0.30%

    Lilly and Novo Cut GLP-1 Prices as Pill Approvals Expand Access

    Eli Lilly and Novo Nordisk are cutting GLP-1 drug prices as oral pill approvals expand access. Lilly's Zepbound shows stronger weight-loss outcomes than Novo's Wegovy. Novo's oral GLP-1 pill, expected to be cheaper, broadens access. Both companies are expanding into adjacent conditions, enhancing long-term investment prospects. Pricing and access are central, with agreed price cuts and expanded Medicare coverage. Competition in the GLP-1 market is set to intensify with new entrants like Pfizer.

    GuruFocus·
    US
    NVO
    -0.30%
    US
    LLY
    +0.07%
    GuruFocus·
    US
    NVO
    -0.30%
    US
    LLY
    +0.07%
    Posts
    View More

    US stocks opened with the Dow down 0.1%, the Nasdaq flat, Nvidia down 0.03%, Tesla up 0.4%, and Novo Nordisk surging 9.6%

    In our pre-mkt summary for Subscribers: Stocks held onto gains after a 3-day rally led by tech stocks and the prospect of two more Fed rate cuts in 2026 pushed stocks toward new highs. Today’s delaye...

    ..................

    $Novo Nordisk AS(NVO.US)

    On Monday, Wegovy oral weight-loss drug was approved by the FDA and is expected to be launched in the U.S. in January next year. The product is an oral tablet suitable for peop...

    Some + movers in premarket include: $Petco Health and Wellness(WOOF.US) $Urban Outfitters(URBN.US) $Verrica Pharmaceuticals(VRCA.US) $Autodesk(ADSK.US) $Dell Tech(DELL.US) $NetApp(NTAP.US) $Novo Nordi...

    © 2025 Longbridge｜Disclaimer